Clinical Trials Browser

Amyloidosis, Hereditary, Transthyretin-Related, Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis, Amyloid Neuropathies, Familial

NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Phase NA Recruiting

41 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06627309 2026-03-09

Rapid dFLC Response Predict CHR in AL Amyloidosis

Recruiting

50 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT01758042 2026-03-06

BMT

Phase NA Completed

10 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Anemia, Aplastic, Anemia, Sickle Cell, Autoimmune Diseases, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Thalassemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Anemia, Diamond-Blackfan, Renal Insufficiency, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT06569147 2026-03-06

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Phase 1/2 Recruiting

49 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

Clinical Trials

AMYLOCARP

Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

MGUS-PET

A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement

Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

ALPS

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

ReAL

EUREKA

ProDigALIty

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

ITA-WebNet

B-SCR-MM

MED-hATTR

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Rapid dFLC Response Predict CHR in AL Amyloidosis

BMT

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis